Ovarian Cancer—Why Lipids Matter
Guangyuan Zhao(Hebei Medical University), Daniela Matei(Northwestern University)
Cited by 80
Related Papers
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2019|533
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
|Journal of the National Comprehensive Cancer Network|2019|332
EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells
|Oncotarget|2016|90
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
|Clinical Cancer Research|2019|90